NextCure (NASDAQ:NXTC) Major Shareholder Buys $18,676.20 in Stock

NextCure, Inc. (NASDAQ:NXTC) major shareholder Adar1 Capital Management, Llc acquired 3,662 shares of the business’s stock in a transaction dated Friday, November 6th. The stock was acquired at an average price of $5.10 per share, for a total transaction of $18,676.20. Following the purchase, the insider directly owned 737,956 shares of the company’s stock, valued at approximately $3,763,575.60. This trade represents a 0.50% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Thursday, November 5th, Adar1 Capital Management, Llc bought 1,024 shares of NextCure stock. The shares were acquired at an average cost of $5.10 per share, with a total value of $5,222.40.
• On Tuesday, October 27th, Adar1 Capital Management, Llc bought 3,553 shares of NextCure stock. The shares were acquired at an average price of $5.10 per share, with a total value of $18,120.30.
• On Monday, October 26th, Adar1 Capital Management, Llc purchased 1,672 shares of NextCure stock. The stock was acquired at an average cost of $5.03 per share, for a total transaction of $8,410.16.
• On Friday, October 23rd, Adar1 Capital Management, Llc purchased 5,626 shares of NextCure stock. The stock was acquired at an average cost of $4.83 per share, for a total transaction of $27,173.58.

NextCure Trading Up 17.6%

NXTC traded up $0.94 during midday trading on Monday, hitting $6.27. 58,474 shares of the company were exchanged, compared to its average volume of 676,034. The company’s 50 day simple moving average is $6.06 and its 200 day simple moving average is $7.70. The firm has a market capitalization of $22.65 million, a price-to-earnings ratio of -0.72 and a beta of 1.22. NextCure, Inc. has a 1-year low of $1.55 and a 1-year high of $15.74.

NextCure (NASDAQ:NXTC) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($2.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.95) by ($0.85).

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Weiss Ratings cut NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, October 26th. Wall Street Zen upgraded NextCure from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of NextCure in a research note on Thursday, August 13th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, NextCure presently has an average rating of “Hold” and a consensus price target of $20.00.

Hedge Funds Weigh In On NextCure

An institutional investor recently raised its position in NextCure stock. Renaissance Technologies LLC increased its holdings in NextCure, Inc. (NASDAQ:NXTC) by 80.0% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 60,534 shares of the company’s stock after purchasing an additional 26,900 shares during the quarter. Renaissance Technologies LLC owned 1.68% of NextCure worth $647,000 at the end of the most recent reporting period. Institutional investors own 42.65% of the company’s stock.

NextCure Company Profile

NextCure, Inc (NASDAQ: NXTC) is a clinical-stage biotechnology company focused on developing immunomedicines for the treatment of cancer. The company’s research is aimed at identifying and targeting biological mechanisms that suppress the immune system’s ability to recognize and attack tumor cells.

NextCure’s product candidates have included NC318, an antibody designed to target Siglec-6, and NC410, a fusion protein intended to block the LAIR-1 immune-suppressive pathway. These programs have been evaluated in early-stage clinical studies involving patients with advanced solid tumors, with the goal of developing treatments that may restore or enhance anti-tumor immune responses.

Founded in 2015 and headquartered in the United States, NextCure has operated primarily as a research and development company serving the global oncology market through clinical trials and collaborations.